CWP
BNGO icon

Concord Wealth Partners’s Bionano Genomics BNGO Stock Holding History

Concord Wealth Partners’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$1.53K – 269
2025
Q4 		$1.53K Hold
1,000
– – ﹤0.01% 713
2025
Q3 		$1.71K Buy
+1,000
New +$3.18K ﹤0.01% 719
2021
Q2 		– Sell
-1
Closed -$2K – 1045
2021
Q1 		$2K Buy
+1
New +$5.64K ﹤0.01% 804

Other funds holding BNGO

GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Carret Asset Management New York $1.02B AUM 26.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Concord Wealth Partners's BNGO Position: Q1 2026 in Review

Concord Wealth Partners sold out of Bionano Genomics (BNGO) in Q1 2026, closing a stake of 1,000 shares — an estimated $1.53K sold.

Concord Wealth Partners first reported a position in BNGO in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q1 2021. 32 funds tracked by Wall St. Rank hold BNGO as of Q1 2026.

  • Concord Wealth Partners reported no remaining Bionano Genomics position as of Q1 2026 after selling out during the quarter.
  • Concord Wealth Partners sold 1,000 Bionano Genomics shares in Q1 2026, an estimated $1.53K.
  • Concord Wealth Partners first reported a position in Bionano Genomics in Q1 2021 and held it in 3 quarters.
  • Concord Wealth Partners's Bionano Genomics position peaked at $2K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2026.

Based on Concord Wealth Partners's 13F filing for Q1 2026, filed 1 May 2026.